Phase 2 Pancreatic Cancer Trial, Recruiting NCT06412510 Sponsor: Case Comprehensive Cancer Center Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06412510
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 65 or older
  • People diagnosed with advanced (Stage III or IV) epithelial ovarian cancer or fallopian tube cancer
  • People diagnosed with pancreatic cancer (Stage I, II, or III) who are receiving chemotherapy before surgery or other main treatment
  • People diagnosed with locally advanced esophageal (food pipe) cancer who are receiving chemotherapy before surgery or other main treatment
  • People diagnosed with locally advanced muscle-invasive bladder cancer who are receiving chemotherapy before surgery or other main treatment

Who may not be able to join:

  • People whose treating doctor estimates their life expectancy is less than 3 months
  • People who are not able to give informed consent to participate in research
  • People who use a wheelchair or have significant difficulty with physical movement
  • People with serious heart or lung disease classified as NYHA Class III or IV (confirm with trial site)
  • People who have a bowel blockage caused by cancer that requires surgery or special nutritional support through a feeding tube or intravenous nutrition
  • People with any other health condition that the trial investigator believes would put them at greater risk or make participation not in their best interest

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mariam AlHilli, MD, Cleveland Clinic Foundation, Case Comprehensive Cancer Center

Phone: 216-644-0418

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 September 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of adherence as calculated by the compliance percentage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov